

### **REMARKS**

Claims 58-90 are pending in the application. Both of the independent claims (claims 58 and 82) have been amended by this Reply. No new matter has been added.

#### **Remarks Concerning 37 C.F.R. § 1.98(a)(3) and MPEP § 609**

On page 2 of the December 21, 2004 Office Action, the Examiner stated that the Information Disclosure Statement and supplements thereto submitted by Applicants do not comply with the C.F.R. § 1.98(a)(3) requirement that a statement of the relevance of a foreign-language reference be provided when such a reference is included in the Information Disclosure Statement. Applicants acknowledge that several foreign-language references were included in the Information Disclosure Statement and supplements thereto. These foreign language references were submitted, not because of any known applicability, but only based on general knowledge that such references may be material to patentability.

Also on page 2 of the December 21, 2004 Office Action, the Examiner encourages Applicants, pursuant to MPEP § 609, to provide a "concise explanation of why the English language information is being submitted and how it is understood to be relevant." In compliance with those requests from the Examiner, Applicants are now in the process of preparing a Statement of Pertinent References, which shall be submitted to the Examiner within the 3-month time frame for the pending Office Action. Applicants believe that their Statement of Pertinent References will alleviate the Examiner's concerns.

#### **Remarks Concerning Rejections Under 35 U.S.C. §103**

In the December 21, 2004 Office Action, the Examiner did not reject any of the claims under 35 U.S.C. § 102. Applicants thus turn to the rejections under 35 U.S.C. § 103.

On page 2 of the December 21, 2004 Office Action, the Examiner rejected claims 58-90 as being unpatentable over U.S. Patent No. 6,233,525 B1 to Langley et al. ("Langley") in view of U.S. Patent No. 5,781,442 to Engleson et al. ("Engleson"), in further view of U.S. Patent No.

6,451,203 B2 to Brown ("Brown"), and in still further view of U.S. Patent No. 5,132,026 to Baluyot ("Baluyot"). Applicants respectfully traverse that rejection.

The Examiner cited all of the aforementioned references in rejecting all of the pending claims 58-90. However, the Examiner cited only Langley in view of Brown in rejecting the two independent claims, 58 and 82. In light of the amendments made herein to those two claims, Applicants will distinguish those two claims over Langley in view of Brown, rendering the Examiner's arguments moot with respect to the dependent claims.

Claims 58 and 82 of the present application are directed to a system for monitoring a portion of a blood component collection procedure in a blood collection facility, including a system server for monitoring a blood collection component collection instrument ("the instrument") during *and throughout* the operation of the instrument.

Specifically, Claim 58 requires a "system server being operably connected to the blood component collection instrument during *and throughout* the operation of the blood component collection instrument" (emphasis added). Likewise, Claim 82 calls for a computer-readable medium for use in an operator interface for monitoring a blood component collection procedure, wherein a segment of the medium is for "reading information from a blood component collection instrument during *and throughout* the operation of the blood component collection instrument" (emphasis added).

None of the references cited by the Examiner, either alone or in combination, discloses either a server for monitoring the instrument during and throughout the operation of the instrument, as in claim 58, or a segment for reading information from the instrument during and throughout the operation of the instrument, as in claim 82. Langley relates to a blood component collection optimization system. A blood component collection procedure is optimized based on a set of process parameters, and the collection procedure is performed based on the optimized parameters. Langley does not disclose monitoring the instrument during the blood collection procedure; Langley discloses only transmitting the parameters to the collection device. As the Examiner observed, Langley discloses that those parameters may be transmitted to the device during the blood collection procedure (col. 13, ll. 40-44). However, as the Examiner also observed on page 13 of the December 21, 2004 Office Action, Langley does not disclose *monitoring or reading information from* the instrument during the collection procedure.

Brown fails to cure the deficiencies of Langley. Brown relates to a system and method for separating whole blood into red blood cells and plasma within a rotating centrifugal separation device. The system includes an "instrument manager" for communicating "with low level peripheral controllers" (col. 7, ll. 21-23). The instrument manager also "conveys back to the application control manager status data about the operational and functional conditions of the processing procedure" (col. 7, ll. 36-39). However, Brown differs from the present application in two significant respects. First, Brown is an entirely self-contained system for the separation of blood into red cell and plasma components; there is no server in Brown, much less a server that monitors a blood *collection* procedure. Second, Brown does not disclose monitoring a blood collection procedure *throughout* the procedure, as the independent claims (as amended) of the instant application now require.

Applicants therefore submit that the combined teachings of Langley and Brown do not satisfy the independent claims of the present application. Specifically, neither of those references, either alone or in combination, discloses a server that monitors a blood collection procedure during and throughout the entirety of the procedure.

In addition to failing to disclose each of the limitations of the independent claims of the present application, the combination of Langley and Brown is improper because there is no motivation or incentive in the prior art to combine those references in the manner suggested by the Examiner (In re Napier, (Fed. Cir. 1995), 55 F.3d 610, 613). Obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the prior art (In re Fine, (Fed. Cir. 1988), 837 F.2d 1071, 5 USPQ2d 1596; In re Jones, (Fed. Cir. 1992), 958 F.2d 347, 21 USPQ2d 1941).

To establish a *prima facie* case of obviousness, three basic criteria must be met. First, there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference or to combine reference teachings. Second, there must be a reasonable expectation of success. Finally, the prior art reference(s) must teach or suggest all of the claim limitations. The teaching or suggestion to make the claimed combinations and the reasonable expectation of success must

both be found in the prior art, not in the applicant's disclosure (In re Vaeck, (Fed. Cir. 1991), 947 F.2d 488, 20 USPQ2d 1438). The Examiner bears the initial burden of factually supporting any prima facie conclusion of obviousness (MPEP § 2142). In the present case, the Examiner has failed to meet that burden.

Langley is from the networked blood collection field, as is the present application, with an emphasis on optimizing the procedure using process parameters. Brown, on the other hand, discusses a way to use a self-contained centrifuge system for separating already-collected blood into different components. On page 14 of the December 21, 2004 Office Action, the Examiner stated that it would have been obvious to combine Langley and Brown because Langley "collects blood and would require process monitoring [from Brown] to enable the optimizer of Langley to perform its function." However, the Langley disclosure indicates that its disclosed system is already capable of performing the optimizing function, without the process monitoring disclosed by Brown. The Examiner's suggestion to combine Langley and Brown is therefore not disclosed in either Langley or Brown. Neither of those references, nor any other prior art in either of those fields, includes any suggestion that the system provided by Langley would be helpful, advantageous or operative if combined with Brown as suggested by the Examiner. Moreover, the Examiner's proposed impetus for combining Langley and Brown would render redundant the optimization process of Langley. As a result, there is no showing of any motivation to combine the references.

Instead, it appears that the Examiner used hindsight in making the suggested combination. However, hindsight combination of references, using the present invention as a roadmap, is improper. It is well recognized that the claimed invention cannot be used as an instruction manual or template to piece together the teachings of the prior art in an attempt to render the claimed invention obvious (In re Fritch, (Fed. Cir. 1991), 972 F.2d 1260, 1266). Most importantly, and as previously stated, neither Langley nor Brown discloses monitoring a blood collection instrument during and *throughout* the entirety of the blood collection procedure, as do the amended independent claims of the present application.

On pages 5-13 of the December 21, 2004 Office Action, the Examiner rejected certain dependent claims as being unpatentable over the combined teachings of Langley, Brown, Engleson and Baluyot, namely claims 59-81 and 83-90. Because the independent claims are all

Application No. 09/865,196  
Attorney Docket No. F-5728 (1417P P 591)  
Reply to Office Action of December 21, 2004

distinguishable over those references for the reasons stated above, and further because there is no motivation to combine those references, the dependent claims of the application are therefore distinguished over those references as well.

Applicants therefore respectfully request that the § 103 rejection be withdrawn.

Application No. 09/865,196  
Attorney Docket No. F-5728 (1417P P 591)  
Reply to Office Action of December 21, 2004


**CONCLUSION**

In light of the amendments made to the independent claims, and the remarks made herein, Applicants submit that Claims 58-90 are in condition for allowance. Applicants respectfully request the Examiner to withdraw the rejections and allow the claims to issue. If it may be of assistance to contact the Applicants regarding the present application, the Examiner is invited to do so. The Commissioner is authorized to charge Deposit Account No. 23-0280 in connection with any fees associated herewith.

Respectfully submitted,

Dated: February 21, 2005

By:

  
James P. Muraff, Reg. No. 39,785  
Wallenstein Wagner & Rockey, Ltd.  
311 South Wacker Drive, 53<sup>rd</sup> Floor  
Chicago, Illinois 60606-6630  
312.554.3300


---

**CERTIFICATE UNDER 37 C.F.R. § 1.10**

Express Mail Label No. EV 497691395 US

Date of Deposit: February 21, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service, postage prepaid, under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Mail Stop AF, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Gillian Gardner/217904